Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.

Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL; CRESCENDO Investigators.

Lancet. 2010 Aug 14;376(9740):517-23. doi: 10.1016/S0140-6736(10)60935-X.

PMID:
20709233
2.

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A.

Lancet. 2007 Nov 17;370(9600):1706-13. Review. Erratum in: Lancet. 2008 Feb 16;371(9612):558.

PMID:
18022033
3.

Cannabinoid type 1 receptor antagonists for smoking cessation.

Cahill K, Ussher MH.

Cochrane Database Syst Rev. 2011 Mar 16;(3):CD005353. doi: 10.1002/14651858.CD005353.pub4. Review.

PMID:
21412887
4.

An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.

Christopoulou FD, Kiortsis DN.

J Clin Pharm Ther. 2011 Feb;36(1):10-8. doi: 10.1111/j.1365-2710.2010.01164.x. Review.

PMID:
21198716
5.

Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.

Cahill K, Ussher M.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005353. Review. Update in: Cochrane Database Syst Rev. 2011;(3):CD005353.

PMID:
17943852
6.

Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.

Cahill K, Ussher M.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005353. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD005353.

PMID:
17636794
7.

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.

Scheen AJ.

J Neuroendocrinol. 2008 May;20 Suppl 1:139-46. doi: 10.1111/j.1365-2826.2008.01681.x. Review.

PMID:
18426513
8.

[The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].

Boekholdt SM, Jukema JW, Peters RJ.

Ned Tijdschr Geneeskd. 2007 Nov 24;151(47):2615-9. Review. Dutch.

PMID:
18161262
9.

Rimonabant for overweight or obesity.

Curioni C, André C.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006162. Review.

PMID:
17054276
10.

Rimonabant for the treatment of overweight and obese people.

Burch J, McKenna C, Palmer S, Norman G, Glanville J, Sculpher M, Woolacott N.

Health Technol Assess. 2009 Oct;13 Suppl 3:13-22. doi: 10.3310/hta13suppl3/03. Review.

11.

Rimonabant: endocannabinoid inhibition for the metabolic syndrome.

Wierzbicki AS.

Int J Clin Pract. 2006 Dec;60(12):1697-706. Review. Erratum in: Int J Clin Pract. 2007 Mar;61(3):534.

PMID:
17109677
12.
13.

Rimonabant: new data and emerging experience.

Wright SM, Dikkers C, Aronne LJ.

Curr Atheroscler Rep. 2008 Feb;10(1):71-8. Review.

PMID:
18366988
14.

The endocannabinoid system as a novel approach for managing obesity.

Lillo JL.

J Am Osteopath Assoc. 2007 Apr;107(4 Suppl 2):S12-20. Review.

PMID:
17784530
15.

Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.

Chavez-Tapia NC, Tellez-Avila FI, Bedogni G, Crocè LS, Masutti F, Tiribelli C.

BMC Gastroenterol. 2009 Oct 9;9:75. doi: 10.1186/1471-230X-9-75. Review.

16.

Rimonabant for the treatment of obesity.

Samat A, Tomlinson B, Taheri S, Thomas GN.

Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):187-93. Review.

PMID:
18991793
Items per page

Supplemental Content

Write to the Help Desk